Day One Biopharmaceuticals Inc.’s (DAWN) Tovorafenib, proposed as monotherapy in relapsed or progressive pediatric low-grade glioma, is under FDA review, with a decision expected on April 30, 2024.Tovorafenib is an oral, brain-penetrant, highly-selective type II RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in primary brain tumors or brain metastases of solid tumor.The vast majority of patients with pediatric low-grade glioma lack approved therapies, and existing treatments come with potential short-term and long-term adverse effects.XOMA Corp. (XOMA) is entitled to receive potential royalty economics related to Tovorafenib.DAWN is currently (Mar.28, 2024) trading at $16.37, up 3.67%.